Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure — a case report and brief review of the literature  by Rybniker, Jan et al.
International Journal of Infectious Diseases 14 (2010) e522–e525Case Report
Treatment of visceral leishmaniasis with intravenous pentamidine and oral
ﬂuconazole in an HIV-positive patient with chronic renal failure — a case report
and brief review of the literature
Jan Rybniker a, Valentin Goede a, Jessica Mertens b, Monika Ortmann c, Wolfgang Kulas d,
Matthias Kochanek a, Thomas Benzing e, Jose´ R. Arribas f, Gerd Fa¨tkenheuer a,*
a 1st Department of Internal Medicine, University of Cologne, 50924 Cologne, Germany
bDepartment of Gastroenterology, University of Cologne, Cologne, Germany
c Institute of Pathology, University of Cologne, Cologne, Germany
dNephrologisches Zentrum Mettmann, Mettmann, Germany
eDepartment of Medicine and Centre for Molecular Medicine, University of Cologne, Cologne, Germany
f Enfermedades Infecciosas, Hospital Universitario La Paz, Madrid, Spain
A R T I C L E I N F O
Article history:
Received 3 March 2009
Accepted 4 June 2009









S U M M A R Y
We report the case of an HIV-positive patient with visceral leishmaniasis and several relapses after
treatmentwith the two ﬁrst-line anti-leishmanial drugs, liposomal amphotericin B andmiltefosine. End-
stage renal failure occurred in 2007 when the patient was on long-term treatment with miltefosine. A
relapse of leishmaniasis in 2008 was successfully treated with a novel combination regimen of
intravenous pentamidine and oral ﬂuconazole. Secondary prophylaxis with ﬂuconazole monotherapy
did not prevent parasitological relapse of leishmaniasis.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Co-infectionwith HIV and Leishmania spp is a well known entity
in southern Europe and an emerging problem inmany low-income
countries. As the incidence rate in Mediterranean Europe has
stabilized with the advent of antiretroviral therapy (ART), the
numbers of co-infected patients are likely to increase substantially
in other parts of the world.1 For example the rate of HIV-infected
patients with visceral leishmaniasis (VL) in some Ethiopian
populations is as high as 15–30%.2
The simultaneous infection with both pathogens has multiple
negative sequelae on the outcomeof both diseases,withdevastating
effects for the patient. It is believed that parasitic infection leads to
chronic immune activation, which induces increased viral load and
rapid progression to AIDS.3 Subsequently, this leads to the* Corresponding author. Tel.: +49 221 478 3324; fax: +49 221 478 5915.
E-mail address: g.faetkenheuer@uni-koeln.de (G. Fa¨tkenheuer).
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.06.010uncontrolled multiplication of Leishmania parasites and often
results in severe atypical clinical presentations of the disease
involving the skin, gastrointestinal tract, and the lungs.4
The major challenge in dually infected patients is the
administration of a successful treatment regimen during the acute
phase of leishmaniasis and to provide potent secondary prophy-
laxis to prevent relapses. This is complicated by the fact that in
contrast to HIV-negative subjects, HIV-positive individuals show
higher rates of drug toxicity and relapses, as well as lower cure
rates with initial treatment. First-line drugs for the treatment of VL
in both HIV-infected and non-infected patients are the lipid
formulations of amphotericin B (L-AMB), miltefosine, and penta-
valent antimonials.1 However, several studies investigating these
drugs as a monotherapy in co-infected individuals have shown
only moderate success rates with regard to initial cure and
relapses. In a randomized comparative trial of European patients
infected with HIV and Leishmania infantum, meglumine antimo-
nate was tested against amphotericin B. The response rates were
66% (29 of 44 patients) for meglumine antimonate and 62% (28 ofses. Published by Elsevier Ltd. All rights reserved.
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were as high as 46%.5 Miltefosine, an orally administered drug, was
studied in a randomized trial in Ethiopia with a favorable response
rate of 89% (56 of 63 patients). However, relapses were seen in 31%
(16 of 52 patients).6 Miltefosine has also been applied with some
success in cases with recurrent leishmaniasis in HIV-infected
individuals.7,8
Currently there are no data available on the efﬁcacy of second-
line drugs such as pentamidine, paromomycin, or ﬂuconazole in
HIV-infected patients. In the absence of data from clinical trials,
many experts currently recommend combination therapy for both
co-infected and mono-infected VL patients.1 However, in pre-
treated patients unresponsive to one or several ﬁrst-line drugs,
options are scarce and clinicians are forced to use unusual drug
combinations with unknown outcome and side effects. Here we
report the case of a Leishmania–HIV co-infected patient with
multiple relapses of VL.
2. Case report
A 49-year-old Caucasian HIV-positive patient was diagnosed
with VL in 2002. The HIV-infection was diagnosed in 1986 and
antiretroviral therapy (ART) was started in 1992. Antiretroviral
therapy regimens contained nucleoside reverse transcriptase
inhibitors (NRTI) only until 1996, when the protease inhibitor
(PI) indinavir was added. Since 2005 the patient has been treated
with a regimen of two protease inhibitors (atazanavir and
saquinavir) boosted with ritonavir. Since 2002, when VL was
diagnosed, viral load was permanently below the limit of
detection, except for a temporary rise in 2005, and the nadir
CD4+ T-cell count was 180 cells/ml. Due to an oropharyngeal
candidiasis in 1989, the patient was classiﬁed as CDC stage B3
(Centers for Disease Control and Prevention).Figure 1. (A) Dermal inﬂammation of the nose during the second relapse; scrapings were
due to VL. (C) and (D) Giemsa stains of duodenal mucosa; multiple Leishmania amastiIn 2002 VL manifested with multiple nodular subcutaneous
lesions of the extremities, generalized arthralgia, and hepatos-
plenomegaly. Before 2002 the patient had undertaken several
journeys to southern European countries, making VL a possible
diagnosis. Histological examination of cutaneous lesions and a
bone marrow aspirate revealed amastigote parasites. Subsequent
PCR assays of these samples were positive for the Leishmania
donovani complex. The patient received L-AMB at 300 mg per day
for 6 days, followed by 300 mg per week for 5 weeks. Secondary
prophylaxis was performed with 300 mg L-AMB per month.
Initially this regimen led to a good clinical response. However, the
patient relapsed 6 months after initiation of treatment despite
being under L-AMB prophylaxis. Subsequently oral treatment
with miltefosine (50 mg twice daily) was initiated in March 2003
and given for 2 months. Clinical and parasitological cure was
achieved,which lasted for several years. InMarch 2007 thepatient
relapsed with multiple facial skin lesions (Figure 1A), hepatos-
plenomegaly, and anemia (hemoglobin 10.7 g/dl). Both dermal
scrapings and peripheral blood samples were positive for
Leishmania in culture and in PCR assays. A second treatment
coursewithmiltefosine (50 mg twicedaily)was started,which led
to a gradual clinical improvement. However, PCR-negativity of
peripheral blood could not be achieved. In September 2007, after 6
months of treatment with miltefosine, the patient developed
acute renal failure and all drugs were discontinued. Renal biopsy
showed severe exudative and necrotizing glomerulonephritis
with extracapillary proliferation. As a consequence the patient
developed chronic renal failure and he has required permanent
hemodialysis since then. Antiretroviral therapy with boosted
atazanavir and saquinavir was successfully reinitiated. In January
2008, the patient complained of epigastric pain, nausea, and
vomiting. Gastroscopy showed erosive gastritis and duodenitis,
and the histopathological examination of gastric biopsies wasLeishmania-PCR positive. (B) Gastric antrum (prepyloric area) with erosive gastritis
gotes inside macrophages of the duodenal lamina propria (C: 630; D: 1000).
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dermal scrapings from multiple cutaneous lesions as well as of
peripheral blood samples were positive for Leishmania. Intrave-
nous pentamidine (300 mg once daily) together with oral
ﬂuconazole (200 mg once daily) was administered for 3 weeks.
A rapid improvement of all clinical symptoms was observed, and
biopsies of a second gastroscopy did not show Leishmania
amastigotes. Furthermore, PCR assays of peripheral blood
samples were negative. After 3 weeks of treatment the patient
complained of peripheral neuropathy and taste disorders. These
symptoms gradually resolved after discontinuation of pentami-
dine. For secondary prophylaxis a combination regimen of
intravenous pentamidine twice per month and oral ﬂuconazole
was proposed but declined by the patient due to his experience of
adverse effects with pentamidine. Thus oral ﬂuconazole (400 mg
daily)was administered for secondary prophylaxis. A Leishmania-
PCR from blood after 2 months remained negative. However, a
blood PCR taken 5 months after termination of intravenous
treatmentwas positive despite continuation of oral ﬂuconazole as
secondary prophylaxis. At this time-point there were no clinical
signs of relapse.
3. Discussion
This case illustrates several difﬁculties in themanagement of VL
in HIV-infected patients. First, treatment with the ﬁrst-line drugs
liposomal amphotericin B and miltefosine was only temporarily
successful, and relapses of VL forced the administration of
combination therapy with second-line drugs of unknown efﬁcacy.
Although resistance testing of Leishmania was not performed, the
clinical course indicates the gradual development of multi-drug
resistance against amphotericin B andmiltefosine. However, it was
recently shown that relapses after amphotericin B treatment do
not always correlate with in vitro drug resistance of the parasites,
and the authors of this study hypothesize that repetitive treatment
with L-AMB may be an option for the management of relapses in
HIV–VL co-infected patients.9
Second, chronic renal failure occurred during long-term
treatment with miltefosine and further limited therapeutic
options. Third, despite complete virological suppression under
ART, the patient presented with multiple relapses of severe
disseminated VL, and his CD4+ T-cell count remained stable at
about 200 cells/ml. Thus, the vicious circle of chronic opportunistic
infection and immune suppression is amajor obstacle to long-term
remission of VL in this patient.
Since pentavalent antimonials are known to cause serious side
effects at a much higher rate in HIV-infected patients,10 we
decided to use a second-line treatment with intravenous
pentamidine and oral ﬂuconazole. Dosage adjustments of penta-
midine are not recommended with the creatinine clearance as low
as 35ml/min and the plasma concentration is not affected by
hemodialyis.11 Due to the complicated course of VL in this patient
we decided to administer pentamidine without dose reduction and
to closely monitor for possible adverse effects. Major side effects of
intravenous pentamidine include rashes, hyper- or hypoglycemia,
hypotension, leuko- and thrombocytopenia, as well as hepato-
toxicity. None of these complications were seen in our patient.
However, after 3 weeks of therapy the patient developed
peripheral neuropathy, which appears to be a rare side effect of
pentamidine.
Oral ﬂuconazole is well tolerated in most patients and has a
proven effect on cutaneous leishmaniasis caused by Leishmania
major.12 A series of 21 Indian VL patients were treated with oral
ﬂuconazole leading to clinical and parasitological cure in 11
patients, however a high relapse ratewas seen in these patients, for
which no secondary prophylaxis was received.13The case reported here should encourage the use of oral
ﬂuconazole in combination with potent ﬁrst-line anti-leishmanial
drugs in future trials of both co-infected and mono-infected
patients. The well-known safety proﬁle of ﬂuconazole and its oral
application may be favorable aspects, especially during long-term
treatment and secondary prophylaxis. However, this case also
demonstrates the limitations of monotherapy. Therefore, ﬂucona-
zole should be regarded as a drug that always has to be
accompanied by other active compounds in the treatment of
leishmaniasis.
While renal failure in this patient occurred during long-term
treatment with miltefosine and nephrotoxicity has been described
as a rare side effect of this drug,14 other factors such as HIV
infection itself and disseminated VL may have caused kidney
failure in this case. The patient presented with rapidly progressive
glomerulonephritis. Kidney biopsy conﬁrmed extracapillary
necrotizing nephritis, but the underlying cause of this condition
could not be deﬁnitively clariﬁed.
Several studies have shown a beneﬁcial effect of ART on the
mortality of HIV-infected patients.15 However, recurrences of VL
are common in HIV-infected patients, and ART does not seem to
reduce the relapse rate. ART in this patient consisted of the two
protease inhibitors atazanavir and saquinavir, boosted with
ritonavir, without the addition of NRTIs. This regimen has led to
increases in CD4+ T-cells in a subgroup of patients with poor
immunological recovery despite virological suppression.16
Unfortunately, this effect was not present in the patient
described here. Of note, there are reports showing in vitro
activity of PIs such as saquinavir against L. infantum and L. major.1
In the absence of clinical studies, it cannot be concluded that this
effect may have contributed to the treatment outcome in our
patient.
In conclusion, we have described an HIV-infected patient with
several episodes of VL, who was successfully treated with a novel
combination of intravenous pentamidine and oral ﬂuconazole.
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